Key result
Olaratumab combined with doxorubicin has shown an improved overall survival compared to doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma.
Why the study?
Does olaratumab in combination with doxorubicin improve overall survival in patients with advanced/metastatic soft tissue sarcoma compared to doxorubicin alone?
Does olaratumab in combination with doxorubicin improve overall survival in patients with advanced/metastatic soft tissue sarcoma compared to doxorubicin alone?
Olaratumab combined with doxorubicin represents a promising treatment strategy that improves overall survival in advanced soft tissue sarcoma, pending phase III confirmation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for olaratumab in advanced STS; phase III confirmation required before clinical adoption.
INTRODUCTION: Olaratumab, a human monoclonal antibody against platelet derived growth factor receptor alpha (PDGFR- α), is the first drug that in combination with doxorubicin for the treatment of patients with advanced/metastatic soft tissue sarcoma (STS) that has showed an improved overall survival compared to doxorubicin alone. These initial results are exciting and have the potential to change the landscape of treatment for patients with STS. Areas covered: This article reviews the development of olaratumab for oncology use by reviewing articles in PubMed for 'platelet derived growth factor' and 'receptor' and 'soft tissue sarcoma'. We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.
No takes yet. Share an insight, caveat, or question.
Okuno et al. (2017) conducted a review in advanced/metastatic soft tissue sarcoma (STS). Olaratumab in combination with doxorubicin vs. doxorubicin alone was evaluated on overall survival. Olaratumab combined with doxorubicin has shown an improved overall survival compared to doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: